Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem Inc (NQ: VSTM )

4.255 -7.925 (-65.07%)
Streaming Delayed Price Updated: 1:19 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verastem Inc

< Previous 1 2 3 Next >
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
Via AB Newswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
Verastem Oncology Announces Reverse Stock Split
From Verastem Oncology
Via Business Wire
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
From Verastem Oncology
Via Business Wire
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Appoints Rob Gagnon to Board of Directors
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology Appoints Anil Kapur to Board of Directors
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.